1 | Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. (Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice MC, Puskas J, Kandzari DE, Karmpaliotis D, Brown WM 3rd, Lembo NJ, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogáts G, Mansour S, Noiseux N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman PE, Bochenek A, Schampaert E, Pagé P, Modolo R, Gregson J, Simonton CA, Mehran R, Kosmidou I, Généreux P, Crowley A, Dressler O, Serruys PW, EXCEL Trial Investigators) N Engl J Med 2019 Nov 07;381(19):1820-1830 520 Citations |
1 | 2017 Update in perioperative medicine: 6 questions answered. (Munyon R, Cohn SL, Slawski B, Smetana GW, Pfeifer K) Cleve Clin J Med 2017 Nov;84(11):863-872 7 Citations |
1 | Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. (Stone GW, Sabik JF, Serruys PW, Simonton CA, Généreux P, Puskas J, Kandzari DE, Morice MC, Lembo N, Brown WM 3rd, Taggart DP, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogáts G, Mansour S, Noiseux N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman P, Bochenek A, Schampaert E, Pagé P, Dressler O, Kosmidou I, Mehran R, Pocock SJ, Kappetein AP, EXCEL Trial Investigators) N Engl J Med 2016 Dec 08;375(23):2223-2235 832 Citations |
1 | Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations. (Lencioni R, Aliberti C, de Baere T, Garcia-Monaco R, Narayanan G, O'Grady E, Rilling WS, Walker D, Martin RC) J Vasc Interv Radiol 2014 Mar;25(3):365-9 48 Citations |
1 | Statin therapy in patients with chronic kidney disease undergoing percutaneous coronary intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry). (Dasari TW, Cohen DJ, Kleiman NS, Keyes MJ, Yen CH, Hanna EB, Saucedo JF) Am J Cardiol 2014 Feb 15;113(4):621-5 13 Citations |
2 | In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry. (Tolerico PH, Cohen DJ, Kleiman NS, Berger PB, Brilakis ES, Piana RN, Shammo S, Keyes MJ, Kennedy KF, Massaro JM, Saucedo JF, EVENT Investigators) Catheter Cardiovasc Interv 2012 Dec 01;80(7):1127-36 6 Citations |
1 | Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stents in saphenous vein grafts: intravascular ultrasonography analysis of the SOS (Stenting of Saphenous Vein Grafts) trial. (Jeroudi OM, Abdel-Karim AR, Michael TT, Lichtenwalter C, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Raghunathan D, DaSilva M, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES) EuroIntervention 2011 Dec;7(8):948-54 6 Citations |
1 | Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: insights from the SOS (Stenting of Saphenous Vein Grafts) trial. (Michael TT, Abdel-karim AR, Papayannis A, Lichtenwalter C, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger PB, Banerjee S, Brilakis ES) J Invasive Cardiol 2011 Jun;23(6):216-9 2 Citations |
1 | Drug eluting versus bare metal stents in cardiac allograft vasculopathy: a systematic review of literature. (Dasari TW, Hennebry TA, Hanna EB, Saucedo JF) Catheter Cardiovasc Interv 2011 Jun 01;77(7):962-9 38 Citations |
1 | Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. (Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S) JACC Cardiovasc Interv 2011 Feb;4(2):176-82 93 Citations |
1 | Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry. (Brilakis ES, Cohen DJ, Kleiman NS, Pencina M, Nassif D, Saucedo J, Piana RN, Banerjee S, Keyes MJ, Yen CH, Berger PB) Am Heart J 2011 Feb;161(2):360-6 20 Citations |
1 | Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era. (Lopez JJ, Keyes MJ, Nathan S, Piana R, Pencina M, Dhar G, Marso S, Rao S, Shammo S, Marquardt W, Cohen DJ, Kleiman NS) Am Heart J 2010 Oct;160(4):767-74 11 Citations |
1 | Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial. (Badhey N, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Addo TA, Haagen D, Abdel-Karim AR, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger PB, Banerjee S, Brilakis ES) Catheter Cardiovasc Interv 2010 Aug 01;76(2):263-9 26 Citations |
1 | Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (PReventing Amputations using Drug eluting StEnts) trial. (Feiring AJ, Krahn M, Nelson L, Wesolowski A, Eastwood D, Szabo A) J Am Coll Cardiol 2010 Apr 13;55(15):1580-9 157 Citations |
1 | Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system. (Wang Q, Pierson W, Sood P, Bol C, Cannon L, Gordon P, Saucedo J, Sudhir K) J Interv Cardiol 2010 Feb;23(1):26-32 12 Citations |
1 | Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. (Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Holper EM, Haagen D, Saeed B, Iturbe JM, Shunk K, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES) JACC Cardiovasc Interv 2009 Sep;2(9):855-60 42 Citations |
1 | Characterization of post-operative risk associated with prior drug-eluting stent use. (Anwaruddin S, Askari AT, Saudye H, Batizy L, Houghtaling PL, Alamoudi M, Militello M, Muhammad K, Kapadia S, Ellis SG) JACC Cardiovasc Interv 2009 Jun;2(6):542-9 75 Citations |
1 | In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. (Latif F, Kleiman NS, Cohen DJ, Pencina MJ, Yen CH, Cutlip DE, Moliterno DJ, Nassif D, Lopez JJ, Saucedo JF, EVENT Investigators) JACC Cardiovasc Interv 2009 Jan;2(1):37-45 134 Citations |
1 | A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. (Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S) J Am Coll Cardiol 2009 Mar 17;53(11):919-28 192 Citations |
1 | Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. (Ramana RK, Ronan A, Cohoon K, Homan D, Sutherland J, Steen L, Liu J, Loeb H, Lewis BE) Catheter Cardiovasc Interv 2008 Jun 01;71(7):886-93 38 Citations |
1 | Discontinuation of antiplatelet therapy prior to low-risk noncardiac surgery in patients with drug-eluting stents: a retrospective cohort study. (Brotman DJ, Bakhru M, Saber W, Aneja A, Bhatt DL, Tillan-Martinez K, Jaffer AK) J Hosp Med 2007 Nov;2(6):378-84 31 Citations |